JP2022547551A5 - - Google Patents

Info

Publication number
JP2022547551A5
JP2022547551A5 JP2022515824A JP2022515824A JP2022547551A5 JP 2022547551 A5 JP2022547551 A5 JP 2022547551A5 JP 2022515824 A JP2022515824 A JP 2022515824A JP 2022515824 A JP2022515824 A JP 2022515824A JP 2022547551 A5 JP2022547551 A5 JP 2022547551A5
Authority
JP
Japan
Prior art keywords
antibody
hepatitis
recombinant
virus
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547551A (ja
JP7629649B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050509 external-priority patent/WO2021050954A1/en
Publication of JP2022547551A publication Critical patent/JP2022547551A/ja
Publication of JP2022547551A5 publication Critical patent/JP2022547551A5/ja
Application granted granted Critical
Publication of JP7629649B2 publication Critical patent/JP7629649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515824A 2019-09-11 2020-09-11 Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法 Active JP7629649B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898735P 2019-09-11 2019-09-11
US62/898,735 2019-09-11
US202062982276P 2020-02-27 2020-02-27
US62/982,276 2020-02-27
PCT/US2020/050509 WO2021050954A1 (en) 2019-09-11 2020-09-11 Compositions and methods related to human neutralizing antibodies to hepatitis b

Publications (3)

Publication Number Publication Date
JP2022547551A JP2022547551A (ja) 2022-11-14
JP2022547551A5 true JP2022547551A5 (https=) 2023-09-07
JP7629649B2 JP7629649B2 (ja) 2025-02-14

Family

ID=74866658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515824A Active JP7629649B2 (ja) 2019-09-11 2020-09-11 Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法

Country Status (7)

Country Link
US (1) US20220315645A1 (https=)
EP (1) EP4021503A4 (https=)
JP (1) JP7629649B2 (https=)
KR (1) KR20220080102A (https=)
CN (1) CN114728066A (https=)
CA (1) CA3154556A1 (https=)
WO (1) WO2021050954A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500515A (ja) * 1986-06-20 1989-02-23 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Ｂ型肝炎ウィルス表面抗原のプレｓ領域のｔ及びｂ細胞エピトープ
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
KR20150070181A (ko) * 2012-09-27 2015-06-24 크루셀 홀란드 비.브이. B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Similar Documents

Publication Publication Date Title
RU2694412C9 (ru) Моноклональные антитела и способы их применения
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
JP2012518425A5 (https=)
JP2018166506A5 (https=)
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
JP2015506945A5 (https=)
JP2005528914A5 (https=)
WO2022216223A1 (en) Vaccine and/or antibody for viral infection
RU2016135962A (ru) Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI
CN113508140A (zh) 与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
CN102264393B (zh) 作为治疗和预防hcv感染药物的抗hcv单克隆抗体
CN113527473A (zh) 一种全人源单克隆抗体及其应用
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
CN108350064A (zh) 针对细胞内抗原的单结构域抗体
JP2023518225A5 (https=)
CN106749644B (zh) 一种全人源抗hcv的中和抗体-trn1001
WO2025077519A1 (zh) 抗人tigit抗体或其功能性片段及其应用
TW202003582A (zh) 頭頸癌之治療
CN115819582A (zh) Pvrig的抗体或其抗原结合片段及其应用
WO2022044573A1 (ja) コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
JP2022547551A5 (https=)
WO2019128119A1 (zh) 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
WO2023125289A1 (zh) 抗pd-1抗体及其用途
CN116178530A (zh) 抗体在治疗SARS-CoV-2感染的用途
WO2022179535A1 (zh) 抗SARS-CoV-2核衣壳蛋白的单克隆抗体及其制备方法和用途